newsfilter
← Latest News
ACCESS Newswire·

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

85% remission rate observed in evaluable frontline AML patientsMipletamig combination enables rare pathway to transplant in a previously ineligible unfit patientNo dose-limiting toxicities observed among evaluable